Drug Profile
Zolantidine
Alternative Names: SKF 95282Latest Information Update: 21 Jan 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antihistamines
- Mechanism of Action Histamine H2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 22 Jun 2001 No-Development-Reported for CNS disorders in Italy (Unknown route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 28 Jul 1998 Preclinical development for CNS disorders in Italy (Unknown route)